IntroductionPrurigo is a common primary chronic skin disease which highly affects quality of life. Clinical subtypes include prurigo nodularis and excoriated (simplex) prurigo, often associated in the same patients. A minor eczematous component may sometimes be associated, but prurigo differs from pruritus associated with other dermatoses such as bullous pemphigoid, atopic dermatitis, Sézary syndrome and scabies. Therapeutic recommendations of prurigo are scarce due to the lack of previously published strong data. Topical corticosteroids, H1‐antihistamine drugs, moisturizing ointments and phototherapy may be non‐effective. Thalidomide has shown clinical benefit, but its long‐term use is limited by side‐effects. Consequently, treatment may be challenging in patients with difficult‐to‐treat prurigo, that is, with failure of conventional therapies.Methotrexate (MTX) is a folic acid antagonist that has proven its efficacy and good tolerance profile in inflammatory dermatoses (atopic dermatitis, psoriasis, bullous pemphigoid). Only one study investigating the efficacy of MTX in 13 patients with prurigo, showing encouraging results, has been published. The aim of our study was to assess the efficacy and safety of MTX in the treatment of difficult‐to‐treat prurigo in a larger series of patients.Materials and methodsIn this retrospective, multicentre study, cases were recruited within six French university dermatology departments, using the coding of
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud